Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Adenovirus Vector COVID-19 Vaccines Followed by mRNA Booster in Cancer Patients
TCTR20220112004Recruiting
- Sponsor
- Quality Improvement fund, King chulalongkorn Memorial Hospital,The Thai Red Cross Society
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of tozinameran in coronavirus disease 2019 (COVID-19) and cancer, sponsored by Quality Improvement fund, King chulalongkorn Memorial Hospital,The Thai Red Cross Society. Primary endpoints: Safety of mRNA COVID-19 booster in cancer patients previously vaccinated with adenovirus vector vaccines and Immunogenicity of mRNA COVID-19 booster in cancer patients previously vaccinated with adenovirus vector vaccines. Started Jun 2021; status: recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)cancer
Beyond the preview
Go deeper on TCTR20220112004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220112004.